Bairuiji Biomedical

Changzhou Bairuiji Biomedical Pharmaceuticals is a leading Chinese biopharmaceutical company specializing in the development and commercialization of advanced biomaterials and regenerative medicine products. Founded in 2008 by Dr. Xiaozheng Shu, the company utilizes a proprietary self-crosslinking and biomimetic materials platform to address clinical needs in post-operative wound healing and tissue repair. Its core portfolio includes a series of Class III medical devices, such as cross-linked sodium hyaluronate gels for preventing intrauterine, pelvic, and nasal adhesions, which have achieved significant market penetration in China and are exported to international markets. Bairuiji has also successfully diversified into the functional skincare sector with its "VITREGEN" brand, targeting sensitive skin and aesthetic repair. The company is currently transitioning to a listing on the Beijing Stock Exchange, reflecting its robust financial growth and innovation in surgical consumables and medical aesthetics.